Kornimate/medical-research-clean huggingface dataset:
multiplex pcr for severe respiratory infections during the covid-19 pandemic

Conditions: Viral Pneumonia

Summary: the hypothesis was that a retrospective investigation of the molecular virological tests in a university hospital could be informative, with the aim to identify non-covid-19 respiratory viruses during the circulation of sars-cov-2, according to systematic population data for public health knowledge.

the hypothesis was that a retrospective investigation of the molecular virological tests in a university hospital could be informative, with the aim to identify non-covid-19 respiratory viruses during the circulation of sars-cov-2, according to systematic population data for public health knowledge: * the main goal was to perform a retrospective investigation of the molecular virological tests in a university hospital, in order to identify non-covid-19 respiratory viruses from the beginning of 2021 to mid-2022 during the circulation of sars-cov-2, for public health knowledge; * the secondary aim was to retrospectively analyze, for a small subgroup of patients from an intensive care unit, the files of patients with positive molecular virological tests for non-covid-19 respiratory viruses from the beginning of 2021 to mid-2022, reporting the following standard-of-care data: (i) the identification of the viruses, (ii) bioclinical features, (iii) medical impact of virological results in real life.

Eligibility criteria:
inclusion criteria: * for adult patients, or minors 'via' parents, able to give consent - 18 intensive care patients exclusion criteria: * non-inclusion in case of refusal

Keywords: respiratory virus
safety and efficacy of rifabutin in patients for non-hiv patients

Conditions: Tuberculosis; Non-tuberculous Mycobacterial Diseases (Including MAC Disease)

Summary: the objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the lpd (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

all the patients whom an investigator prescribes the first mycobutin® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Eligibility criteria:
inclusion criteria: * patients need to be administered mycobutin® in order to be enrolled in the surveillance. exclusion criteria: * patients not administered mycobutin®.
clinical efficacy of intense pulsed light(ipl) procedure in dry eye patient

Conditions: Dry Eye Syndromes

Summary: clinical efficacy of intense pulsed light(ipl) procedure in dry eye patients with meibomian gland dysfunction prior to cataract surgery.

ipl procedure is a device used for symptom relief and treatment of dry eye syndrome caused by meibomian gland dysfunction in adults, and its safety and long-term effects have been confirmed. the purpose of this study is to determine whether this procedure before cataract surgery is effective in improving the symptoms of dry eye syndrome after cataract surgery.

Eligibility criteria:
inclusion criteria: 1. a patient at the age of 21 cataract surgery 2. a patient has the visual potential of 20/25 or better in each eye after cataract removal 3. dry eye patient by meibomian gland dysfunction 4. written informed consent to surgery and participation in the study exclusion criteria: 1. eye damage, active eye infection 2. uncontrolled health problem 3. wear contact lens within one month 4. allergic reactions of fluorescein sodium or ophtalmic anesthetic 5. eye surgery and trauma in the last six months 6. eye disease, structural abnormality 7. if there is a cause of vision loss other than cataracts 8. under 20/25 expect vision 9. under the age of 20 years of age 10. pregnant woman and lactating woman 11. medical conditions in which ipl is contraindicated
technology-supported treatment of sleep apnea in prediabetes

Conditions: Sleep Apnea; PreDiabetes; Overweight or Obesity

Summary: despite the efficacy of intensive lifestyle interventions in prediabetes, the incidence of diabetes is rising, and thus there is a critical need for additional strategies to prevent diabetes and to reduce its cardiovascular complications in this high-risk population. sleep apnea is a highly common condition in prediabetes, but it has been mostly ignored and undertreated in current practice. the proposed study will be the first to assess whether adding cpap (continuous positive air pressure) treatment to a lifestyle intervention improves cardiometabolic outcomes beyond that achieved with lifestyle alone (i.e. current standard of care) in high-risk individuals with prediabetes.

this is a 6-month randomized controlled, parallel group trial with two arms. after baseline, the subjects will be randomized to lifestyle intervention alone (lifestyle group) or lifestyle plus cpap intervention (lifestyle plus cpap group). the same metabolic and cardiovascular assessments will be performed at baseline and after 6-months of intervention. the lifestyle group will aim to achieve a weight loss through diet and exercise. the lifestyle plus cpap group will additionally receive cpap treatment. all subjects will use a custom smartphone app to track weight loss and/or cpap goals and will receive weekly coaching phone calls to maximize treatment adherence.

Eligibility criteria:
inclusion criteria: * overweight or obese * prediabetes * sleep apnea exclusion criteria: * diabetic * enrolled in a formal weight loss program * any underlying disease likely to limit life span and/or increase risk of interventions
a study of blood pressure and blood supply to the brain in persons with a spinal cord injury.

Conditions: Orthostatic Hypotension; Spinal Cord Injuries

Summary: the purpose of this study is to determine how blood pressure and blood flow are controlled during head-up tilt in a semi-upright position. in this investigation we are studying blood pressure and blood flow to the brain, with and without a medication which lowers blood pressure (vasotec). we will determine how persons with a spinal cord injury are able to maintain blood flow to the brain (not get dizzy) as they assume a more upright position and their blood pressure decreases.

individuals with tetraplegia lack normal sympathetic nervous system regulation of blood pressure and, therefore, relative hypotension is a common occurrence. this hypotension may be more pronounced with postural stress. loss in mental acuity and sometimes even consciousness is an associated symptom of postural hypotension in individuals with tetraplegia. there is some evidence to suggest that although mean arterial blood pressure (map) is relatively low in these individuals, middle cerebral arterial blood flow (cbf) may be maintained. consequently, individuals with chronic tetraplegia often compensate and are stable in the seated upright position. autoregulation of cbf has been defined as the stability of cerebral blood flow throughout a range of systemic blood pressures (map). this proposal will examine systemic hemodynamics and middle cerebral artery blood flow during hut with and without vasotec, an angiotensin ii inhibitor. by partially or completely ablating the renin-angiotensin system, which is postulated to play a major role in blood pressure regulation, the potential dissociation between systemic blood pressure and middle cerebral artery blood flow, in individuals with tetraplegia, may be demonstrated. the aim is to determine whether persons with chronic tetraplegia are able to maintain similar cbf, or similar cbf changes, as able-bodied controls despite a greater decrease in map to the same hypotensive challenge. the relationship between map and cbf has not been defined in this population. understanding this relationship may lead to improved screening and treatment for prevention of postural hypotension in persons with tetraplegia.

Eligibility criteria:
inclusion criteria: * duration of spinal cord injury (sci) at least 1 year * level of sci c4-8 and t6 and below * matched non-sci subjects * chronological age between 18-65 years * euhydration: subjects will be instructed to avoid caffeine and alcohol and to maintain normal salt and water intake for several days prior to study. exclusion criteria: * known heart and/or blood vessel disease * dehydration * high blood pressure * kidney disease * diabetes mellitus * prescribed ace inhibitors * acute infection * smoking * pregnancy

Keywords: blood pressure, low hypotension, postural injuries, spinal cord spinal cord transection spinal cord trauma
zanubrutinib, in combination with lenalidomide, with or without rituximab in participants with relapsed/refractory diffuse large b-cell lymphoma

Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Summary: the primary objective of this study is to determine the maximum tolerated doses (mtd) and the recommended phase 2 dose (rp2d), and safety, tolerability, and efficacy of zanubrutinib in combination with lenalidomide in participants with r/r dlbcl


Eligibility criteria:
key inclusion criteria: 1. histologically confirmed dlbcl, all participants must provide sufficient archival or fresh tumor tissue samples for evaluation by immunohistochemistry (ihc) and gene expression profiling (gep). 2. relapsed or refractory disease, defined as either: 1) progression of disease after having achieved disease remission (complete response \[cr\] or partial response \[pr\]) , or 2) stable disease (sd), or progressive disease (pd) at completion of the treatment regimen preceding entry to the study. 3. participants who have not received high dose therapy/stem cell transplantation (hdt/sct) must be ineligible for hdt/sct. 4. measurable disease as defined by at least 1 lymph node \>1.5 cm in longest diameter, or at least 1 extra-nodal lesion \>1.0 cm in longest diameter, and measurable in 2 perpendicular dimensions. 5. received an appropriate first-line therapy for dlbcl,defined as an anti cd20 antibody and an appropriate anthracycline-based combination therapy for at least 2 cycles, unless the patient is intolerant or had disease progression before cycle 2.. key exclusion criteria: 1. current or history of central nervous system (cns) lymphoma. 2. histologically transformed lymphoma. 3. history of allogeneic stem-cell transplantation. 4. prior exposure to a btk inhibitor. 5. prior exposure to lenalidomide or thalidomide. note: other protocol defined inclusion/exclusion criteria may apply.
maintenance of platelet inhibition with cangrelor

Conditions: Acute Coronary Syndrome (ACS)

Summary: the purpose of this study is to demonstrate that patients receiving cangrelor infusion before coronary artery bypass grafting have an acceptable safety profile and can undergo surgery without excessive bleeding peri-operatively.


Eligibility criteria:
inclusion criteria: * written informed consent * 18 years of age * non emergent coronary bypass graft surgery * received a thienopyridine within 48 hours prior to enrollment exclusion criteria: * confirmed or suspected pregnancy * cerebrovascular accident within one yar * intracranial neoplasm * history of bleeding diathesis * thrombocytopenia
endostar durative transfusion combining with gemcitabine-cisplatin to treat non-small cell lung cancer (nsclc)

Conditions: Non-small Cell Lung Cancer

Summary: the purpose of this study is to determine whether endostar pumping into vein with gemcitabine-cisplatin are more effective than endostar with gemcitabine-cisplatin regularly in the treatment of non-small cell lung cancer (nsclc).

endostar have anti-tumor activity by against vascular endothelial growth factor for initial treatment. this study was designed to evaluate the safety and efficacy of endostar continued vein-pumping combining with gemcitabine-cisplatin (gp)chemotherapy in patients with nsclc,and seeking for more effective injection.

Eligibility criteria:
inclusion criteria: 1. histologically or cytologically diagnosed nsclc; 2. primary treatment,inoperable stage iiib/iv nsclc; 3. age of 18-75years; gender not required; 4. adequate hematologic, renal, and hepatic function ,specific index as follows: liver function: s-bilirubin ≤1.5 uln ; transaminase≤2 uln. renal function: s-creatinine ≤1.2 uln; blood urea nitrogen ≤1.2 uln . uln: upper normal limit. marrow hemopoietic function: wbc≥4.0×10\^9/l, anc≥2.0×10\^9/l platelet count ≥100×10\^9/l, hb≥100 g/l; 5. ecog ps 0-2,life expectancy ≥ 3 months; endure more than two cycle chemotherapy; 6. the patients have explicit lung tumor lesions and the lesions were measurable; (according to the standard of recist1.1, they should have at least one of accurately measurable lesions with the largest diameter ≥ 10mm by spiral ct, mri); 7. no history of serious drug allergy; 8. informed consent should be obtained before treatment. exclusion criteria: 1. symptomatic brain metastases with cognitive disorder,bone metastases with complications; 2. major organ dysfunction and serious heart disease( congestive heart-failure,incontrollable high-risk arrhythmia,unstable angina, valvular disease, myocardial infarct and resistant hypertension,); 3. serious complications and investigator consider it is unsuited enrolling; 4. pregnant or lactating women; 5. allergic to research drug; 6. participating in other experimental trials and receive the treatment in four weeks; 7. the position that is for observing curative effect have a radiotherapy.

Keywords: endostar advanced non-small cell lung cancer continued pumping into vein gemcitabine carboplatin
safety and efficacy study of mim-d3 ophthalmic solution for the treatment of dry eye

Conditions: Dry Eye

Summary: the objective of this study is to compare the safety and efficacy of 1% mim-d3 and 5% mim-d3 to placebo for the treatment of the signs and symptoms of dry eye.


Eligibility criteria:
inclusion criteria: 1. be at least 18 years of age 2. provide written informed consent 3. have a reported history of dry eye 4. have a history of use or desire to use eye drops for dry eye exclusion criteria: 1. be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation (e.g. follicular conjunctivitis) at visit 1, or have been diagnosed with ocular rosacea, or any viral or bacterial disease of the cornea or conjunctiva, within the last 12 months 2. have any planned ocular and/or lid surgeries over the study period 3. have corrected visual acuity greater than or equal to +0.7 as assessed by early treatment of diabetic retinopathy study (etdrs) scale in both eyes at visit 1 4. have an uncontrolled systemic disease 5. be a woman who is pregnant, nursing or planning a pregnancy 6. be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom; iud; or surgical sterilization of partner. for non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use adequate birth control as defined above for the remainder of the study 7. have a known allergy and/or sensitivity to the test article or its components 8. have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study 9. be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 45 days of visit 1 10. be unable or unwilling to follow instructions, including participation in all study assessments and visits
contrast enhanced (ce) ultrasound and ce computed tomography or ce magnetic resonance imaging in liver masses

Conditions: Liver Tumors

Summary: this comparison study is performed to show equivalence of ceus with cect or cemr to diagnose noninvasively focal liver masses. this is a multi-center prospective cohort study of 250 subjects, which will be performed at four institutions in canada. subjects with a focal liver mass, measuring at least 2.5 centimeters in maximal diameter, will undergo a conventional baseline sonogram followed by a contrast enhanced ultrasound (ceus). ceus will be performed on standard ultrasound scanners with contrast specific imaging capability. the contrast agent used is definity (lantheus medical imaging, billerica,ma) all subjects will have either a dedicated hepatic contrast enhanced ct or mr scan within 60 days of the ceus as per the standard of care in the institution. anonymized image files from all imaging will be shown independently to two readers, blinded to all clinical and demographic data, who will predict malignancy and diagnosis.

this comparison study is performed to show equivalence of ceus with cect or cemr to diagnose noninvasively focal liver masses. this is a multi-center prospective cohort study of 250 subjects, which will be performed at four institutions in canada. subjects with a focal liver mass, measuring at least 2.5 centimeters in maximal diameter, will undergo a conventional baseline sonogram followed by a contrast enhanced ultrasound (ceus). ceus will be performed on standard ultrasound scanners with contrast specific imaging capability. the contrast agent used is definity (lantheus medical imaging, billerica,ma) all subjects will have either a dedicated hepatic contrast enhanced ct or mr scan within 60 days of the ceus as per the standard of care in the institution. anonymized image files from all imaging will be shown independently to two readers, blinded to all clinical and demographic data, who will predict malignancy and diagnosis.

Eligibility criteria:
inclusion criteria: * an incidental liver mass amenable to us evaluation * undiagnosed liver mass * mass threshold size is 2.5 cm * source of subjects: * liver mass found on conventional institutional us * liver mass detected on ct and mri that remain uncategorized * referral of patient with a liver mass following detection in outside institution. * confirmatory ct or mri performed within 60 days of initial scan according to the institutional protocols exclusion criteria: * any known pre existing mass * pregnancy * severe or unstable cardiac disease, including angina, congestive heart failure, or arrhythmias * severe copd * pulmonary hypertension * bidirectional shunts * transient right to left shunts * known hypersensitivity to definity or any of its components

Keywords: contrast enhanced ultrasound (ceus) liver tumors hepatocellular carcinoma hemangioma focal nodular hyperplasia hepatic metastases
continous renal replacement therapy with the carpediem® in a french national cohort of 25 neonates and small infants

Conditions: Hypoxic-Ischemic Encephalopathy; Sepsis; Kidney Diseases; Metabolic Disease; Twin to Twin Transfusion Syndrome; Cardiac Disease; Pulmonary Disease

Summary: historically, ckrt and hemodialysis were performed in small infants and newborns with devices developed for adults with high rates of complications and mortality. we aim to retrospectively report the first multicenter french experience of carpediem® use and evaluate the efficacy, feasibility, outcomes, and technical considerations of this new device in a population of neonates and small infant. compared to adult's device continuous renal replacement therapy with an adapted machine allowed successful blood purification without severe complications even in low birth weight neonates.


Eligibility criteria:
inclusion criteria: * children and neonates including premature and low birth weight neonates * have a diagnosis of acute kidney injury, end stage renal disease, metabolic disease, electrolyte abnormality * require renal replacement therapy exclusion criteria: -renal replacement therapy with another device than carpediem machine
early feasibility study of the edwards forma tricuspid transcatheter repair system

Conditions: Tricuspid Valve Regurgitation

Summary: the study is a multi-center, prospective, early feasibility study to measure individual patient clinical outcomes and effectiveness, evaluate the safety and function, provide guidance for future clinical study designs and development efforts of the edwards forma tricuspid transcatheter repair system.

the early feasibility study of the edwards forma tricuspid transcatheter repair system is a multi-center, prospective, early feasibility study to measure individual patient clinical outcomes and effectiveness, evaluate the safety and function, provide guidance for future clinical study designs and development efforts of the edwards forma tricuspid transcatheter repair system. data collected in this clinical study will include safety and function of the investigational system as well as up to 3 year clinical outcomes.

Eligibility criteria:
inclusion criteria: 1. ≥ 18 years old 2. clinically significant, symptomatic, functional, tricuspid regurgitation (per applicable guidelines) requiring transcatheter tricuspid valve repair as assessed by the local heart team exclusion criteria: 1. tricuspid valve/right heart anatomy not suitable for the study device 2. moderate or greater tricuspid valve stenosis 3. severe rv dysfunction
pharmacokinetics of voxilaprevir in adults with normal hepatic function and moderate or severe hepatic impairment

Conditions: HCV Infection

Summary: the primary objective of this study is to evaluate the pharmacokinetics (pk), safety, and tolerability of a single dose of voxilaprevir (formerly gs-9857) in participants with normal hepatic function, moderate hepatic impairment and severe hepatic impairment. participants in the healthy control group will be matched to participants with impaired hepatic function by gender, age (± 10 years), and body mass index (± 15%).


Eligibility criteria:
key inclusion criteria: * all individuals: * screening laboratory values within defined thresholds for group * use of two effective contraception methods if female of childbearing potential or sexually active male * for individuals with moderate hepatic impairment: * diagnosis of chronic (\> 6 months) hepatic impairment * score on the child-pugh-turcotte (cpt) scale of 7-9 at screening (child pugh class b). * for individuals with severe hepatic impairment: * diagnosis of chronic (\> 6 months) hepatic impairment * score on the cpt scale of 10-15 at screening (child pugh class c) * for individuals with normal hepatic function: * hepatitis c virus (hcv) antibody and hepatitis b surface antigen negative key exclusion criteria: * all individuals: * pregnant or nursing female or male with pregnant female partner * hiv infection * history of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment or compliance with the protocol * for individuals with moderate or severe hepatic impairment: * active hcv infection * current hepatic encephalopathy * variceal bleeding in the last 6 months unless banded * prior placement of a portosystemic shunt * history of hepatorenal or hepatopulmonary syndrome * spontaneous bacterial peritonitis currently or within the last 6 months * hospitalization within the last 2 months related to cirrhosis * confirmed hypotension * suspicion of hepatocellular carcinoma note: other protocol defined inclusion/exclusion criteria may apply.